Evolving approaches with interferon alfa in chronic myelogenous leukemia
Morra, E.; Alimena, G.; Lazzarino, M.; Liberati, A.M.; Montefusco, E.; Bernasconi, P.; Mancini, M.; Donti, E.; Merante, S.; Caricchi, P.
Seminars in Hematology 30(3 Suppl 3: 26-27
1993
ISSN/ISBN: 0037-1963 PMID: 8235701 Document Number: 411342
Document emailed within 1 workday
Related Documents
Guilhot, F. 1993: Interferon alfa and low-dose cytosine-arabinoside for the treatment of patients with chronic myelogenous leukemia in chronic phase. French CML Study Group Seminars in Hematology 30(3 Suppl 3: 24-25Opalka, B.; Wandl, U.; Beer, U.; Roggenbuck, U.; Kloke, O.; Niederle, N. 1991: Breakpoint localization within the M-bcr and clinical course do not correlate in patients with chronic myelogenous leukemia undergoing alfa interferon therapy Leukemia 5(6): 452-456
Fernández, I.; Castellano, G.; Canga, F.; Colina, F.; García, H.; Fuertes, A.; Casis, B.; Martín, A.; Solís, J.A. 1995: A comparative randomized controlled study of the efficacy of interferon alfa-2b and interferon alfa-2a in the treatment of chronic hepatitis C Gastroenterologia y Hepatologia 18(2): 66-72
Guilhot, F. 1994: The role of interferon in the treatment of chronic myelogenous leukemia in chronic phase Nouvelle Revue Francaise d'Hematologie 36(Suppl 1): S39-S46
Tóthová, E.; Stecová, N.; Kafková, A.; Fricová, M.; Svorcová, E. 2002: Occurrence of autoimmune complications in patients with chronic myelocytic leukemia during treatment with interferon alfa Vnitrni Lekarstvi 48(5): 380-383
Guilhot, F.; Dreyfus, B.; Desmarest, M.C.; Giraud, C.; Huret, J.L.; Brizard, A.; Tanzer, J. 1989: Combined therapy interferon and chemotherapy in chronic myelogenous leukemia Nouvelle Revue Francaise d'Hematologie 31(2): 171-173
Uehara, E.; Uesugi, T.; Tasaka, T.; Matsuhashi, Y.; Tamura, T.; Kuwajima, M.; Nagai, M. 2002: Reversible cardiomyopathy secondary to interferon-alpha in chronic myelogenous leukemia Gan to Kagaku Ryoho. Cancer and ChemoTherapy 29(2): 317-321
McGlave, P.; Mamus, S.; Vilen, B.; Dewald, G. 1987: Effect of recombinant gamma interferon on chronic myelogenous leukemia bone marrow progenitors Experimental Hematology 15(4): 331-335
Armenta, D.; Espallargas, C.; Paz, A.; Rodríguez Martorel, J.; Ladines, R.; Alvarez, C.; Román, J.; Andrés, P. 1996: Complete cytogenetic remission of chronic myeloid leukemia with low-dose interferon alfa-2b and monthly high-dose busulfan Sangre 41(6): 465-467
Riedel, D.; Lindemann, A.; Otto, J.; Brennscheidt, U.; Lübbert, M.; Mertelsmann, R.; Herrmann, F. 1990: Gamma-interferon interrupts growth stimulation in chronic myelogenous leukemia established by endogenous granulocyte colony-stimulating factor Leukemia 4(11): 786-789
Nevens, F.; Van Vlierberghe, H.; D'Heygere, E.; Delwaide, J.; Adler, M.; Henrion, J.; Lenaerts, A.; Hendlisz, A.; Michielsen, P.; Bastens, B.; Brenard, R.; Laureys, A. 2010: A randomized, open-label, multicenter study evaluating the efficacy of peginterferon alfa-2a versus interferon alfa-2a, in combination with ribavirin, in naïve and relapsed chronic hepatitis C patients Acta Gastro-Enterologica Belgica 73(2): 223-228
Urabe, A.; Asano, S.; Mizoguchi, H.; Aoki, N.; Takaku, F. 2000: Long-term follow up of chronic myelogenous leukemia patients treated with natural interferon alpha--multi-institutional cooperative study Gan to Kagaku Ryoho. Cancer and ChemoTherapy 27(10): 1541-1546
Wong, J. B.; Nevens, F. 2002: Cost-effectiveness of peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin as initial treatment of chronic hepatitis C in Belgium Acta Gastro-Enterologica Belgica 65(2): 110-111
Guilhot, F.; Guerci, A.; Fiere, D.; Harousseau, J.L.; Maloisel, F.; Bouabdallah, R.; Guyotat, D.; Rochant, H.; Najman, A.; Nicolini, F.; Colombat, P.; Abgrall, J.F.; Ifrah, N.; Brière, J.; Bauters, F.; Navarro, M.; Morice, P.; Bordessoule, D.; Vilque, J.P.; Desablens, B.; Tertian, G.; Blanc, M.; Chastang, C.; Tanzer, J. 1996: The treatment of chronic myelogenous leukemia by interferon and cytosine-arabinoside: rational and design of the French trials. French CML Study Group Bone Marrow Transplantation 17(Suppl 3): S29-S31
Neuwirtová, R.; Cermák, J.; Kvasnicka, J.; Sedlácková, M. 1989: Treatment of hairy-cell leukemia using interferon alfa Casopis Lekaru Ceskych 128(34): 1065-1070
Gómez-Almaguer, D.; Jaime-Pérez, J.C.; Herrera-Garza, J.L.; González-Llano, O. 1998: Intermittent interferon alfa in the treatment of hairy cell leukemia Revista de Investigacion Clinica; Organo del Hospital de Enfermedades de la Nutricion 50(4): 331-334
2001: Treatment of chronic hepatitis B: interferon alfa first Prescrire International 10(51): 17-21
Machiulaĭtene, E.R.; Lasunskaia, E.B.; Nefedova, I.B.; Perekalina, T.A.; Salogub, G.N.; Poliakova, L.E. 1996: The use of interferon-alfa (reaferon) in patients with chronic myeloleukemia Terapevticheskii Arkhiv 68(10): 44-47
Cianciara, J.; Laskus, T.; Hryniewicz, H.; Jabłońska, J.; Loch, T. 1991: Treatment of chronic hepatitis B with interferon alfa-2b (Intron A) Przeglad Epidemiologiczny 45(4): 315-320
Reiffers, J.; Goldman, J.; Meloni, G.; Cahn, J.Y.; Gratwohl, A. 1994: Autologous stem cell transplantation in chronic myelogenous leukemia: a retrospective analysis of the European Group for Bone Marrow Transplantation. Chronic Leukemia Working Party of the EBMT Bone Marrow Transplantation 14(3): 407-410